AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12452235 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg epidural morphine
Number of subjects: 90
Study 12452235 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg epidural morphine
Number of subjects: 90
Study 12452235 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg epidural morphine
Number of subjects: 90
Study 10510952 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose (100 mg t.d.s.)
Number of subjects: 89
Study 10510952 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (850 mg b.d.)
Number of subjects: 89
Study 10510952 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study 8543942 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine
Number of subjects: 0
Study 8543942 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1688013 — intervention group
Group type: EXPERIMENTAL
Intervention: Remoxipride
Number of subjects: 20
Study 1688013 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 20
Study 6758825 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg twice daily for 2 weeks)
Number of subjects: 5
Study 30573006 — intervention group
Group type: EXPERIMENTAL
Intervention: Training at home using a mobile box trainer
Number of subjects: 36
Study 30573006 — intervention group
Group type: COMPARATOR
Intervention: Standard training without home access
Number of subjects: 36
Study 28328847 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 0.15% isopropyl unoprostone (IU) used 3 times a day for 54 weeks
Number of subjects: 52
Study 28328847 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 26416412 — intervention group
Group type: EXPERIMENTAL
Intervention: Oropharyngeal dysphagia patients with acute pneumonia (OD-APN)
Number of subjects: 47
Study 26416412 — intervention group
Group type: EXPERIMENTAL
Intervention: Oropharyngeal dysphagia patients with prior pneumonia (OD-PNP)
Number of subjects: 47
Study 26416412 — intervention group
Group type: EXPERIMENTAL
Intervention: Oropharyngeal dysphagia patients without pneumonia (OD)
Number of subjects: 47
Study 26416412 — intervention group
Group type: COMPARATOR
Intervention: Older controls without OD (H)
Number of subjects: 47
Study 23317926 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein drink (20 g whey protein, 20 g carbohydrates)
Number of subjects: 237
Study 23317926 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk protein drink (20 g milk protein, 20 g carbohydrates)
Number of subjects: 237
Study 23317926 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate drink (40 g carbohydrates)
Number of subjects: 237
Study 21501517 — intervention group
Group type: EXPERIMENTAL
Intervention: IFNβ‐1a 22 mcg (low dose, LD)
Number of subjects: 101
Study 21501517 — intervention group
Group type: EXPERIMENTAL
Intervention: IFNβ‐1a 44 mcg (high dose, HD)
Number of subjects: 101
Study 21501517 — intervention group
Group type: COMPARATOR
Intervention: NAb-positive patients
Number of subjects: 101
Study 19524253 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental verbs with strong nonfactive semantics (e.g., /ji5‐wai4/ 'falsely think')
Number of subjects: 100
Study 19524253 — intervention group
Group type: COMPARATOR
Intervention: Control for nonverbal intelligence and general language ability
Number of subjects: 100
Study 17766523 — intervention group
Group type: EXPERIMENTAL
Intervention: Hudson prong bubble continuous positive airway pressure therapy
Number of subjects: 300
Study 17766523 — intervention group
Group type: COMPARATOR
Intervention: Headbox oxygen treatment (standard care)
Number of subjects: 300
Study 15128179 — intervention group
Group type: EXPERIMENTAL
Intervention: Night work (23:00 to 07:00)
Number of subjects: 9
Study 15128179 — intervention group
Group type: COMPARATOR
Intervention: Day shift and night shift
Number of subjects: 9
Study 12930116 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone sodium phosphate (2 mg)
Number of subjects: 45
Study 12930116 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide (10.5 mg)
Number of subjects: 45
Study 12930116 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone sodium succinate (50 mg)
Number of subjects: 45
Study 12930116 — intervention group
Group type: COMPARATOR
Intervention: All three drugs
Number of subjects: 45
Study 9022603 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular injection of recombinant FSH (Puregon)
Number of subjects: 218
Study 9022603 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous injection of recombinant FSH (Puregon)
Number of subjects: 218
Study 7943099 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (60 mg/day)
Number of subjects: 150
Study 7943099 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 2906019 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiprolol
Number of subjects: 0
Study 2906019 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 0
Study 30171823 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported tobacco use
Number of subjects: 2163
Study 30171823 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 2163
Study 30171823 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint replacement, past use of steroids, acid reflux/GERD
Number of subjects: 2163
Study 28635218 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide nasal spray treatment
Number of subjects: 101
Study 28635218 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment of 3.0% saline nasal irrigation and budesonide nasal spray
Number of subjects: 101
Study 28635218 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal irrigation with 3.0% saline
Number of subjects: 101
Study 28635218 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 101
Study 26232815 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (topical sodium chloride, timolol, and betamethasone)
Number of subjects: 45
Study 26232815 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic normobaric oxygen at a flow rate of 10 L/min for 1 hour twice daily for 3 weeks in addition to conventional therapy
Number of subjects: 45
Study 26232815 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcorneal oxygen at a flow rate of 5 L/min for 1 hour twice daily for 3 weeks in addition to conventional therapy
Number of subjects: 45
Study 23927913 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate (2.5 or 5 mg daily for 1 year)
Number of subjects: 147
Study 23927913 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for 1 year)
Number of subjects: 147
Study 23927913 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate (during years 2 and 3)
Number of subjects: 147
Study 23927913 — intervention group
Group type: COMPARATOR
Intervention: Placebo (during years 2 and 3)
Number of subjects: 147
Study 23927913 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate
Number of subjects: 147
Study 23927913 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147
Study 21926632 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir 400 mg twice daily for 21 days (period 1)
Number of subjects: 24
Study 21926632 — intervention group
Group type: EXPERIMENTAL
Intervention: Darunavir/ritonavir 800/100 mg once daily for 14 days (period 2)
Number of subjects: 24
Study 21926632 — intervention group
Group type: EXPERIMENTAL
Intervention: Darunavir/ritonavir 800 mg once daily (period 3)
Number of subjects: 24
Study 21926632 — intervention group
Group type: COMPARATOR
Intervention: Raltegravir 400 mg twice daily (group 1)
Number of subjects: 24
Study 21926632 — intervention group
Group type: EXPERIMENTAL
Intervention: Darunavir/ritonavir alone
Number of subjects: 24
Study 21926632 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir alone
Number of subjects: 24
Study 18310192 — intervention group
Group type: EXPERIMENTAL
Intervention: StudentBodies2‐BED (n = 52)
Number of subjects: 105
Study 18310192 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group (n = 53)
Number of subjects: 105
Study 16754287 — intervention group
Group type: EXPERIMENTAL
Intervention: Awareness Intervention Programme (AIP) for 4 weeks
Number of subjects: 21
Study 16754287 — intervention group
Group type: COMPARATOR
Intervention: Conventional rehabilitation programme for 4 weeks
Number of subjects: 21
Study 12842506 — intervention group
Group type: COMPARATOR
Intervention: OPCAB
Number of subjects: 60
Study 12842506 — intervention group
Group type: COMPARATOR
Intervention: CABG
Number of subjects: 60
Study 10910659 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese pupils
Number of subjects: 0
Study 10910659 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal body weight pupils)
Number of subjects: 0
Study 10910659 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (obese and non-obese pupils)
Number of subjects: 0
Study 8891011 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cyclosporine at 3 mg/kg/day
Number of subjects: 41
Study 8891011 — intervention group
Group type: COMPARATOR
Intervention: Topical 0.05% beta‐methasone‐17,21‐dipropionate (BDP) cream
Number of subjects: 41
Study 1898717 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 20 mg/d (increased to 40 mg/d for some patients)
Number of subjects: 96
Study 1898717 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezafibrate 400 mg/d
Number of subjects: 96
Study 1898717 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 96
Study 1898717 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezafibrate
Number of subjects: 96
Study 6601256 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfisoxazole, 75 mg/kg/d in two divided doses for 3 months
Number of subjects: 35
Study 6601256 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfisoxazole therapy
Number of subjects: 35
Study 6601256 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 6601256 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfisoxazole
Number of subjects: 35
Study 6601256 — intervention group
Group type: COMPARATOR
Intervention: Sulfisoxazole and placebo
Number of subjects: 35
Study 3157939 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyethylene catheters used in group A for a mean period of 9 +/- 1 days
Number of subjects: 84
Study 3157939 — intervention group
Group type: COMPARATOR
Intervention: Teflon catheters used in group B for a mean period of 11 +/- 1 days
Number of subjects: 84
Study 28895787 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based Acceptance and Commitment Therapy (8 weeks)
Number of subjects: 61
Study 28895787 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 61
Study 27364407 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinning physical training program (group C)
Number of subjects: 30
Study 27364407 — intervention group
Group type: EXPERIMENTAL
Intervention: General gymnastics program (group B)
Number of subjects: 30
Study 27364407 — intervention group
Group type: COMPARATOR
Intervention: Diet alone (group A)
Number of subjects: 30
Study 24947578 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive pc-training in addition to conventional treatment
Number of subjects: 35
Study 24947578 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 35
Study 22752440 — intervention group
Group type: COMPARATOR
Intervention: Mg-0 (100 mL of normal saline)
Number of subjects: 88
Study 22752440 — intervention group
Group type: EXPERIMENTAL
Intervention: Mg-25 (25 mg/kg magnesium sulfate)
Number of subjects: 88
Study 22752440 — intervention group
Group type: EXPERIMENTAL
Intervention: Mg-50 (50 mg/kg magnesium sulfate)
Number of subjects: 88
Study 20008620 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasatinib 100 mg once daily
Number of subjects: 50
Study 20008620 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasatinib 50 mg twice daily
Number of subjects: 50
Study 18451774 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant supplement (1 g vitamin C/800 IU vitamin E)
Number of subjects: 19
Study 18451774 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 18451774 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat, low-carbohydrate weight loss diet (HF)
Number of subjects: 19
Study 15989982 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined spinal-epidural block (CSEB)
Number of subjects: 80
Study 15989982 — intervention group
Group type: COMPARATOR
Intervention: Epidural block (EB)
Number of subjects: 80
Study 12854881 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine (30 mg a day, 3 times a day for 15 days)
Number of subjects: 19
Study 12854881 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 10574595 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted PAPNET analysis
Number of subjects: 846
Study 10574595 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional screening
Number of subjects: 846
Study 8916975 — intervention group
Group type: COMPARATOR
Intervention: Antigenemia-guided ganciclovir treatment (placebo group)
Number of subjects: 226
Study 8916975 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganciclovir administered at engraftment (ganciclovir group)
Number of subjects: 226
Study 8916975 — intervention group
Group type: COMPARATOR
Intervention: Antigenemia-guided ganciclovir treatment
Number of subjects: 226
Study 8916975 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganciclovir administered at engraftment
Number of subjects: 226
Study 8916975 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 226
Study 1726208 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefpodoxime proxetil 200mg twice daily for 7 to 14 days
Number of subjects: 251
Study 1726208 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefpodoxime proxetil 400mg twice daily for 7 to 14 days
Number of subjects: 251
Study 1726208 — intervention group
Group type: COMPARATOR
Intervention: Overall (both groups)
Number of subjects: 251
Study 6356004 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicillin C‐R, 50,000 U/kg intramuscularly, followed by penicillin V, 100 mg/kg/d, orally four times a day for three days
Number of subjects: 96
Study 6356004 — intervention group
Group type: COMPARATOR
Intervention: No antibiotic therapy
Number of subjects: 96
Study 30423132 — intervention group
Group type: EXPERIMENTAL
Intervention: Acylcarnitine profile including short- and long-chain acylcarnitines
Number of subjects: 945
Study 30423132 — intervention group
Group type: COMPARATOR
Intervention: Conventional model
Number of subjects: 945
Study 30423132 — intervention group
Group type: EXPERIMENTAL
Intervention: C4OH-carnitine increase
Number of subjects: 945
Study 30423132 — intervention group
Group type: EXPERIMENTAL
Intervention: Model including acylcarnitines
Number of subjects: 945
Study 30233001 — intervention group
Group type: EXPERIMENTAL
Intervention: Corrected‐Assisted‐Synchronized‐Periodic (CASP) therapy
Number of subjects: 61
Study 30233001 — intervention group
Group type: COMPARATOR
Intervention: Conventional passive stretching exercises
Number of subjects: 61
Study 25029567 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 600 mg loading dose
Number of subjects: 63
Study 24942646 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium supplementation (200 mcg oral Se tablets, twice daily)
Number of subjects: 74
Study 24942646 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 22318373 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy (9 sessions over 6 weeks including joint mobilization, exercises, and massage)
Number of subjects: 49
Study 22318373 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 49
Study 22318373 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy
Number of subjects: 49
Study 20051951 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostate cancer screening with PSA serum test (cutoff level of 4.0 ng/ml)
Number of subjects: 0
Study 18034989 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (5‐10 mg)
Number of subjects: 188
Study 18034989 — intervention group
Group type: COMPARATOR
Intervention: Losartan (50‐100 mg)
Number of subjects: 188
Study 18034989 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 188
Study 16220762 — intervention group
Group type: EXPERIMENTAL
Intervention: Transducer-tipped intrauterine pressure catheter
Number of subjects: 249
Study 16220762 — intervention group
Group type: COMPARATOR
Intervention: Air-coupled intrauterine pressure catheter
Number of subjects: 249
Study 11339498 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgrastim (rhG-CSF)
Number of subjects: 80
Study 11339498 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 9734619 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant insulin‐like growth factor‐1 (rhIGF‐1)
Number of subjects: 8
Study 9734619 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of recombinant growth hormone (rhGH) plus recombinant IGF‐1
Number of subjects: 8
Study 8112242 — intervention group
Group type: EXPERIMENTAL
Intervention: PHT before test sessions
Number of subjects: 50
Study 8112242 — intervention group
Group type: COMPARATOR
Intervention: PHT after test sessions
Number of subjects: 50
Study 2847524 — intervention group
Group type: EXPERIMENTAL
Intervention: iproplatin
Number of subjects: 132
Study 2847524 — intervention group
Group type: EXPERIMENTAL
Intervention: carboplatin
Number of subjects: 132
Study 1139766 — intervention group
Group type: EXPERIMENTAL
Intervention: Prick test with allergen extracts
Number of subjects: 153
Study 1139766 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum level of allergen specific IgE
Number of subjects: 153
Study 1139766 — intervention group
Group type: COMPARATOR
Intervention: Negative prick test reaction
Number of subjects: 153
Study 1139766 — intervention group
Group type: COMPARATOR
Intervention: Serum tests results for IgE specific to allergens
Number of subjects: 153
Study 30794553 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee guard device (magnetophoresis delivering Glucosamine, Chondroitin, and Hyaluronic Acid)
Number of subjects: 114
Study 30794553 — intervention group
Group type: COMPARATOR
Intervention: NSAID gel (diclofenac sodium 1%)
Number of subjects: 114
Study 27503605 — intervention group
Group type: EXPERIMENTAL
Intervention: Remind-to-move (RTM) treatment; 25 children, 75 hours over 3 weeks
Number of subjects: 73
Study 27503605 — intervention group
Group type: EXPERIMENTAL
Intervention: Constraint-induced movement therapy (CIMT); 24 children, 75 hours over 3 weeks
Number of subjects: 73
Study 27503605 — intervention group
Group type: COMPARATOR
Intervention: Conventional rehabilitation; 24 children
Number of subjects: 73
Study 26706662 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol acetate (MA)
Number of subjects: 60
Study 26706662 — intervention group
Group type: COMPARATOR
Intervention: Levonorgestrel-containing intrauterine device (LNG-IUD)
Number of subjects: 60
Study 26706662 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with BMI<35
Number of subjects: 60
Study 26706662 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with BMI≥35
Number of subjects: 60
Study 24985000 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (B. animalis subspecies lactis MB 2409, B. bifidum MB 109B, and B. longum subspecies longum BL04) for 3 months
Number of subjects: 38
Study 24985000 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 23186556 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness- and body-psychotherapy-based group treatment
Number of subjects: 36
Study 23186556 — intervention group
Group type: COMPARATOR
Intervention: Control group (waiting time)
Number of subjects: 36
Study 19287181 — intervention group
Group type: EXPERIMENTAL
Intervention: Tripterygium wilfordii Hook F (TwHF)
Number of subjects: 3
Study 19287181 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 3
Study 17213825 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum prostate-specific antigen (PSA) determination
Number of subjects: 30194
Study 17213825 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital rectal examination (DRE)
Number of subjects: 30194
Study 17213825 — intervention group
Group type: EXPERIMENTAL
Intervention: Second screening round
Number of subjects: 30194
Study 15609592 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese herbs (CH)
Number of subjects: 53
Study 15609592 — intervention group
Group type: COMPARATOR
Intervention: Cisapride
Number of subjects: 53
Study 11761341 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Number of subjects: 338
Study 11761341 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 338
Study 9052580 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol (E2) replacement therapy (2 mg/day for 12 weeks)
Number of subjects: 31
Study 9052580 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 8329264 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9% saline with adrenaline 1:200,000
Number of subjects: 80
Study 8329264 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% lignocaine with adrenaline 1:200,000
Number of subjects: 80
Study 8329264 — intervention group
Group type: COMPARATOR
Intervention: 0.5% lignocaine
Number of subjects: 80
Study 8329264 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline
Number of subjects: 80
Study 3520797 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopists with knowledge of radiologic diagnosis
Number of subjects: 156
Study 3520797 — intervention group
Group type: COMPARATOR
Intervention: Endoscopists without knowledge of radiologic diagnosis
Number of subjects: 156
Study 3520797 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall agreement for duodenal ulcer
Number of subjects: 156
Study 3520797 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall agreement for deformity of the duodenal bulb
Number of subjects: 156
Study 3520797 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall agreement for duodenitis
Number of subjects: 156
Study 30177372 — intervention group
Group type: EXPERIMENTAL
Intervention: NTR + TA
Number of subjects: 351
Study 30177372 — intervention group
Group type: EXPERIMENTAL
Intervention: NTR + DVH + TA
Number of subjects: 351